drugset / Trial / NCT01597492

A Study to Evaluate the Effect of Belimumab on Vaccine Responses in Subjects With Systemic Lupus Erythematosus (SLE)

NCT01597492

Phase 4 Completed 79 enrolled GlaxoSmithKline GlaxoSmithKline · collab
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to assess the impact of belimumab on immune response to pneumococcal vaccine in subjects with Systemic Lupus Erythematosus (SLE).

Timeline

Start
2012-05-31
Primary completion
2015-09-01
Completion
2015-09-24

Drugs

EvaluationDrugModalityDoseRoute
Subject Prevnar 13 Vaccine
Background Belimumab Monoclonal antibody 10 mg/kg Intravenous